12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

Open Monoclonal Technology, Pfizer deal

Pfizer received a non-exclusive license to use Open Monoclonal Technology's OmniRat mAb platform for antibody R&D. The OmniRat platform...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >